01:48 PM EST, 01/23/2025 (MT Newswires) -- Vigil Neuroscience ( VIGL ) shares surged over 26% in recent Thursday trading following positive results from a Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease, supporting its advancement to a mid-stage clinical trial.

The initial Phase 1 study demonstrated a favorable safety and tolerability profile for VG-3927 across all subjects, including elderly participants.

VG-3927 achieved a dose-dependent reduction of soluble TREM2 levels in cerebrospinal fluid by about 50% and showed activation of the TREM2 receptor, which is believed to support brain health through microglial activity.

Based on these findings, Vigil said it plans to advance a once-daily oral dose of 25 milligrams into a Phase 2 trial, expected to begin in Q3.

Price: 2.56, Change: +0.53, Percent Change: +26.11